Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Tucker Remmers
Period: Reporting periods mapped to calendar 2025 Q2 – 2025 Q4 (3 quarters).
- Questions
- 3on tracked calls
- Challenge rate
- 0%none of 3 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 3with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 3 of 3 questions from 2 companies
WSTWest Pharmaceutical Services2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2025 Q3
Can you break down how that split between those projects that are in a development or validation phase versus switches that have already been put in place
Show response
Eric confirmed less than 40% of Annex-1 projects have converted to commercial revenue to date. Projects take 3-4 quarters for some and 6-8 quarters for others depending on scale and customer speed.
Calendar 2025 Q2
what are the hurdles to automating that SmartDose device and kind of difficulties of getting that validated
Show response
Eric confirmed SmartDose automation on schedule for late 2025/early 2026 validation and commercialization. Executing dual strategy of cost improvements and automated line validation. Declined to comment on specific margin impact but emphasized focus on both levers.
VEEVVeeva Systems Inc.1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q4
how soon you think you could develop some clinical AI agent
Show response
Peter outlined the timeline: commercial this year, safety and quality by April 2026, clinical operations by end of 2026, clinical data management by end of 2026. eTMF agent for document intake and completeness checking is a prime example.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| WST West Pharmaceutical Services | 2 | —Rate withheld: fewer than 3 questions |
| VEEV Veeva Systems Inc. | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Innovation & R&D2
- Cloud & AI1
- Regulation Policy1
- Revenue Growth1
- Margin1